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Abstract  25 
Beta-hemolytic streptococci of groups C and G, designated as Streptococcus 26 
dysgalactiae (SD), can cause severe and recurring invasive infections. In this case-27 
control study, we aimed to identify clinical and molecular risk factors for recurrence 28 
of SD bacteremia. Twenty-two cases of recurrent SD bacteremia were identified and 29 
median time between episodes was six months. The most frequent clinical 30 
manifestation was skin- and soft-tissue infection. Cases and 92 controls, with single 31 
episode SD bacteremia, showed similar demographics, had similar Charlson 32 
comorbidity scores, and had similar clinical presentations. Thirty days fatality was 13 33 
% among controls whereas none of 22 cases died. In 19 (86%) cases, the same emm 34 
type was encountered in both episodes. SD isolates from recurrent episodes and from 35 
single episodes had a similar emm type distribution. Thus, we did not identify clinical 36 
risk factors for recurrences. The high proportion of identical emm types in recurrent 37 
episodes indicates a host-specific colonization.  38 
 39 
 40 
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1. Introduction 45 
Human pathogenic beta-hemolytic streptococci of groups C and G (GCS and GGS) 46 
have become increasingly recognized as important causes of severe infection [1-3]. 47 
The vast majority of GGS and GCS causing human infections belong to 48 
Streptococcus dysgalactiae (SD) and cause a spectrum of disease similar to that of 49 
Streptococcus pyogenes [3-6]. SD is further divided into subsp. equisimilis which is 50 
beta-hemolytic and can have different Lancefield groups and subsp. dysgalactiae 51 
which is not beta-hemolytic and display Lancefield group C [7]. Otherwise, the two 52 
subspecies are not easily separated by standard methods such as biochemistry or 53 
sequencing of the 16S rRNA gene [7,8]. Among GCS causing human infections, 54 
some isolates are Streptococcs equi [5,9], and some isolates among GGS are 55 
Streptococcus canis [10]. Typing of SD is commonly performed through sequencing 56 
of the emm gene encoding the M protein. The most common focus of invasive SD 57 
infection is skin- and soft tissue, followed by bacteremia of unknown origin, but also 58 
septic arthritis, and infective endocarditis occurs [3]. Invasive infections are 59 
frequently seen in elderly patient and those with underlying medical conditions [5,11]. 60 
The mortality rates in SD bacteremia have been reported to be between 8 and 15 % 61 
[5,11,12]. SD bacteremia has a tendency to recur and rates of recurrence between 3 62 
and 9 % have been reported [6,13-16]. In such reports, up to four recurrences were 63 
described with a median interval of 8 months (range 1-64 months) between the 64 
episodes [3,6,15,17]. There has been some speculation whether or not recurrence is 65 
associated with a specific emm SD type or- clinically- with specific underlying 66 
conditions. In previous case series, recurrence was caused by the same emm type SD 67 
in 7 of 8, 3 of 4, and in 2 of 5 patients and isolates from a given patient displaying the 68 
same emm type were highly genetically related [3,6,15]. The SD emm type causing 69 
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recurrence has varied between reports but StG485.0 [6,17] and StG6 [3] have been 70 
isolated from many cases. These studies were underpowered to detect if particular SD 71 
types are more prone to cause recurrent bacteremia. Studies looking at the clinical 72 
associations reported the presence of genital cancer (particularly cervical cancer), a 73 
history of cellulitis [6], or “chronic lymphatic abnormalities” [15] more frequent in 74 
cases with recurrent SD bacteremia. The present case-control study was performed to 75 
identify bacterial and host factors associated with increased risk for recurrence of SD 76 
bacteremia. 77 
 78 
2. Materials and methods 79 
Cases of recurrent bacteremia with GCS and GGS between 2003 and 2013 were 80 
identified in the databank of the department of clinical microbiology in Malmö/Lund. 81 
The laboratory is the only one serving a population of around 1.2 million inhabitants. 82 
For each case, the two preceding and the two following patients with bacteremia with 83 
SD of the same streptococcal group were selected as controls (i.e. case-control ratio 84 
1:4). The identification of the bacteria by the diagnostic laboratory had depended on a 85 
typical appearance upon Gram-staining and on blood agar as well as on latex 86 
agglutination (Streptex, Remel, Lenexa, KS, USA). We cultured the bacteria on blood 87 
agar in 5% CO2 at 37°C over night and directly transferred them to grids and 88 
subjected them to analysis with Ultraflextreme matrix-assisted laser desorption 89 
ionization - time of flight mass spectrometry (MALDI-TOF MS) (Bruker Daltonics, 90 
Bremen, Germany), using the Biotyper version 3.0 software. A score of above 2.0 91 
was considered to confirm the identification to the species level. The emm gene 92 
encoding the SD M protein was sequenced and type was determined as described 93 
(http://www.cdc.gov/streplab).  94 
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Data on clinical presentation was gathered from the medical records of the respective 95 
patient according to a predefined questionnaire modified from [18]. Sepsis was 96 
assessed as described [19]. The study was approved by the Regional Ethics 97 
Committee in Lund (no 2013/31). Statistical analyses were performed using the Prism 98 
6 software. If not otherwise stated, Fischer’s exact test was used to compare 99 
categorical variables and Mann-Whitney-U test used for continuous variables. A p-100 
value< 0.05 was considered significant. 101 
 102 
3. Results 103 
3.1 Patients with recurrence 104 
Twenty-three patients with recurrent episodes of bacteremia with GCS or GGS were 105 
identified among a total of 593 episodes. Their features are described in table 1. In 19 106 
patients GGS, and in 4 patients GCS was the microorganism causing recurring 107 
bacteremia. When MALDI-TOF MS species identification was used, SD was 108 
demonstrated in 22 cases, and Streptococcus canis (GGS) in one case. In 20 patients 109 
two episodes of bacteremia were recorded, and in three patients three episodes were 110 
identified. The median time between the first and the second episodes was six months 111 
(range 1-53 months), whereas the time interval between the second and third episode 112 
was four, six, and nineteen months respectively. In 19 patients, the recurrence was 113 
caused by the same emm type. In three cases, different emm types were noted. The S. 114 
canis isolate was non-typeable.  115 
Skin- and soft-tissue infection was the most frequent clinical manifestation (17 of 22 116 
patients). Erysipelas was the single most common entity comprising 50 %. In 77 % of 117 
the cases, the clinical presentation was identical in the first and the second episode. 118 
Treatment for the first episode was given with a beta-lactam antibiotic for a minimum 119 
 6 
of 10 days. More SIRS criteria (median 3) were noted on the presentation of a 120 
recurrent episode when compared with the initial episode (median 2), though this 121 
difference was statistically not significant (p=0.2 with Wilcoxons matched-pairs 122 
signed rank test). There were no differences in CRP levels or the number of patients 123 
fulfilling criteria for severe sepsis on initial presentation and presentation at 124 
recurrence. No fatalities were recorded among the 23 patients with recurrence. 125 
 126 
3.2 Comparison of recurrent and single episodes of SD bacteremia 127 
3.2.1 Bacteriological aspects 128 
92 control isolates (76 of GGS and 16 of GCS) were confirmed to be SD by MALDI-129 
TOF MS. The type-distribution of the isolates where the same type caused recurrence 130 
(n=19) were similar to types of isolates (n=92) causing a single episode (Figure 1). 131 
Types StG643, StG480, and StG6 were common in both groups whereas StG485 was 132 
more common in the group with a single episode. 133 
 134 
3.2.2 Clinical characteristics 135 
Table 2 compares the demographic and clinical characteristics of patients with 136 
recurrent and single episode SD bacteremia. A previous history of erysipelas was 137 
more common in the group with recurrence but this difference was not statistically 138 
significant. Table 2 also compares the clinical presentations of patients with recurrent 139 
and single episode SD bacteremia. Erysipelas was the single most common entity 140 
comprising 50 % of patients who later recurred and 38 % of those with a single 141 
episode. Infection foci such as abscesses, bone and joint infections and infections 142 
related to medical procedures and foreign materials were more common in the group 143 
with a single episode. The differences were, however, not statistically significant.  144 
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Five patients (23 %) from the group with recurrent SD bacteremia had an initial 145 
presentation with severe sepsis; in comparison 30 patients (32 %) presented with 146 
severe sepsis in the group with a single SD bacteremia episode (p=0.6). Empirical 147 
treatment was initiated with a broad-spectrum beta lactam (e.g. a cephalosporin or 148 
carbapenems) in 52 % of cases and with a penicillin or cloxacillin in 34 % of cases 149 
with no significant differences between the groups. The total time for intravenous 150 
antibiotics was similar between the groups (7 and 6.5 days respectively) as was the 151 
total time of antibiotic treatment (Table 2). The length of hospital stay was non-152 
significantly longer in the group with a single episode. 153 
There were 12 fatalities (13 %) within 30 days of the positive blood culture in the 154 
control group whereas none of the 23 patients experiencing recurrence died within 30 155 
days of the recurrence (p=0.1).  156 
 157 
4. Discussion 158 
We identified 23 patients with recurrent GCS and GGS bacteremia in 11 years 159 
underlining the observation that SD bacteremia has a tendency to recur. Our study, 160 
despite of being retrospective, is larger than previous case reports/series, has defined 161 
controls, and is population based. We did not identify factors that were significantly 162 
associated with an increased risk for recurrence, apart from the association with 163 
erysipelas in the first episode. Due to the nature of retrospective case-control studies, 164 
the conclusions are limited by the estimates (e.g. clinical assessment) noted in the 165 
patient chart and the relatively small sample size of cases. Nevertheless, the fact that 166 
almost 90% of the recurrences are caused by a pathogen revealing the same emm type 167 
is indicative for a specific host-pathogen colonization association. Moreover, none of 168 
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our patients had a history of intravenous drug use, suggesting an endogenous or host-169 
specific source of recurrent bacteremia.  170 
SD subspecies equisimilis is beta-hemolytic and can display different Lancefield 171 
groups as opposed to subsp. dysgalactiae which is not beta-hemolytic and carries a 172 
Lancefield group C antigen [7]. The SD isolates described here all displayed beta-173 
hemolysis and a majority are Lancefield group G and thus they likely all belong to the 174 
subspecies equisimilis [7], but since MALDI-TOF MS cannot separate this subspecies 175 
from subspecies dysgalactiae we chose not to indicate subspecies [8]. The types 176 
StG6, StG480, and StG485 prevalent in this study have also been reported to be so by 177 
others [2,12,14,20]. Type StG643 comprising 17 % of our isolates was very recently 178 
shown to be common in Norway [21]. Also, looking solely at emm-types, there was 179 
no significant association with increased risk for recurrence. We were not able to 180 
analyze host factors (e.g. HLA types) to review a host-pathogen association as shown 181 
previously with GAS [22]. The risk factors reported previously; genital cancer [6] and 182 
“chronic lymphatic abnormalities” [15], were infrequent among our cases whereas a 183 
history of cellulitis, reported by Liao et al. to be associated with recurrence, was also 184 
observed frequently among our patients with recurrence. 185 
The risk for recurrence in GCS/GGS bacteremia has been reported to be between 3 186 
and 10 % and the majority of recurrences occur within the first year [6,13-16]. We 187 
could confirm this observation in our study. Since bacteremia with SD is associated 188 
with significant mortality and morbidity, the patients and their relatives should be 189 
informed of the risk for recurrence and informed to seek medical care immediately 190 
upon suspicion of recurrence. Intensified efforts to eliminate potential risk factors 191 
such as wounds are also warranted. The use of penicillin prophylaxis is a 192 
controversial issue and the dosing and duration of such treatment is unexplored. In 193 
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selected cases prophylaxis could be considered and we would favor the use of 194 
prophylaxis to patients after recurrence if there is a defined risk factor that cannot be 195 
eliminated. To improve the understanding of SD recurrent bacteremia, future studies 196 
should address if the patients with recurrence are constantly colonized or if they are 197 
reinfected as well as if their antibody response to SD differ from that of patients with 198 
single episodes. 199 
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Legend to figure 296 
Figure 1. Distribution of types among isolates where the same emm type caused the 297 
recurrent episode (n=19) represented with black bars and among isolates from 298 
single episodes (n=92) represented by grey bars. Other isolates include 299 
StG5820, StG245, and StG5420 (n=2), as well as single isolates of StC1400, 300 
StC36, and StC6979. 301 
302 
 13 
Table 1 Characteristics of patients with recurrent episodes of bacteremia with 303 
GCS/CCS 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
 321 
 322 
 323 
 324 
 325 
 326 
 327 
 328 
 329 
Abbreviations used are: CHF, congestive heart failure; RF, renal failure; nt, non-typable; De, dementia; 330 
UF, unknown focus; PE, previous erysipelas; PN, polyneuropathy; DM, diabetes mellitus; KT, kidney 331 
transplanted; CW, chronic wound; WI, wound infection; COPD, chronic obstructive pulmonary 332 
disease; Ob, obesitas; LO, lymphedema; PC, prostate cancer; S, stroke; PD, Parkinssons disease; cyt, 333 
cytostatic drugs; LC, lung cancer; AML, acute myeloic leukemia, PAC, port-á-cath; SLE, systemic 334 
lupus erythematosus; ICU, intensive care unit; DCM, dilated cardiomyopathy; Sa, sarcoidosis; AVP, 335 
aortic valve prosthesis; PH, prostate hyperplasia; RT, radiation therapy; AC, anal cancer; UC, urinary 336 
catheter; HL, Hodgekin lymphoma; Ps, psoriasis, VC, ventricular carcinoma. 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
 354 
Age & 
gender 
Underlying condition Clinical syndrome 
1
st
/2
nd
 episode 
Group 
 
Type Months 
to recur 
90 M CHF, RF Erysipelas GGS StG480/485 13 
87 F De UF/bursitis GGS nt 6 
83 M PE, PN Erysipelas GCS StG652 2 
71 M DM, KT, CW WI GGS StG480 3 
69 F DM, RF, CW, COPD WI GGS StG10 2 
62 M DM, Ob, CW Erysipelas GGS StG6792/ 
652 
27 
56 F LO, PE Erysipelas GGS StG166 23 
87 M De, PC UF/Erysipelas GGS StG485 4 
84 F S, CHF Erysipelas GGS StG480 1 
81 M DM, CW, PD Erysipelas/WI GCS StG62647 1 
79 M PE, cyt for LC Erysipelas GGS StG6 1 
69 F AML, PAC UF/PAC-infection GGS StG2078  
68 F SLE, CHF, COPD Necrotizing 
cellulitis/UF 
GCS StG643 7 
79 M PH, PE Erysipelas GGS StG480 39 
62 F DCM, Sa Erysipelas GGS StG6 12 
80 F AVP UF/Erysipelas GCS StG643 53 
81 M PC, CW WI/WI/osteitis GGS StC74a 2, 6 
75 M PH Cellulitis GGS StG485 8, 6 
70 F RT against AC Myositis/UF GGS StG6 18 
71 M Ob, DM, UC Erysipelas GGS StG6792/ 
6/652 
16, 19 
60 M DM, HL, Ps Cellulitis/Erysipelas GGS StG643 9 
57 M Cyt for VC, PAC UF/PAC-infection GGS StG480 2 
65 M PE, Ob, PN Erysipelas GGS StG483 39 
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Table 2. Comparison of recurrent and single episodes of bacteremia with SD 355 
 356 
Statistical testing was performed with Mann-Whitney U test for continuous variables 357 
and with Fischer´s exact test for categorical variables. 358 
 359 
 360 
 361 
 362 
 
 
Recurrent 
episode (n=22) 
Single episode 
(n=92) 
p for 
difference 
Age, (years, median) 74 74 p=0.6 
Gender (% male) 64 63 p=1 
Charlson comorbidity index (mean, range) 2 (0-6) 1 (0-7) p=0.2 
Underlying disease 
    Diabetes (%) 
 
32 
 
24 
 
p=0.5 
    Chronic leg ulcer (%) 27 11 p=0.09 
    Previous radiation or lymph oedema (%) 14 9 p=0.4 
    Previous erysipelas  23 8 p=0.05 
Clinical Manifestation(%) 
          Skin and soft tissue            
          Bacteraemia without focus 
          Abscess 
          Bone and joint 
          Post operative or device related 
          Endocarditis 
 
67 
23 
0 
0 
0 
0 
 
56 
24 
4 
5 
8 
1 
 
p=0.3 
p=1 
p=1 
p=0.6 
p=0.3 
p=1 
Severe sepsis at presentation (%) 23 32 p=0.6 
Empirical treatment (%) 
          Penicillin or cloxacillin 
          Cephalosporin or carbapenem 
          Other 
          No antibiotic 
 
37 
55 
5 
5 
 
30 
52 
11 
7 
 
p=0.6 
p=1 
p=0.7 
p=1 
Treatment length (days, median) 
          Intravenous 
          Total 
 
6.5 
14 
 
7 
14 
 
p=0.5 
p=1 
Length of stay in the hospital (days, 
median) 
7.5 11 p=0.2 
Fatality proportion (%)  0 13 p=0.1 
    
